文献速递糖尿病肥胖与代谢综合征

技术用于2型糖尿病与糖尿病前期:一项叙述性综述

The use of technology in type 2 diabetes and prediabetes: a narrative review.
PubMed 文献 · Diabetologia · 2024-06-29

本文综述了持续葡萄糖监测、胰岛素泵和闭环系统等技术在2型糖尿病及糖尿病前期人群中的应用证据。持续葡萄糖监测对接受胰岛素或非胰岛素治疗的2型糖尿病患者均有血糖获益,胰岛素泵在2型糖尿病中似乎安全有效,闭环系统初步结果令人期待。

要点

  • 持续葡萄糖监测对接受胰岛素或非胰岛素治疗的2型糖尿病患者均有血糖获益。
  • 胰岛素泵在2型糖尿病中似乎安全有效,尤其适用于HbA1c显著高于目标者。
  • 闭环系统在2型糖尿病中的初步研究结果令人期待,糖尿病前期应用尚需更多数据。

核心结论

  • 持续葡萄糖监测系统对接受胰岛素或非胰岛素治疗的2型糖尿病患者均有血糖获益。
  • 胰岛素泵在2型糖尿病患者中似乎安全有效,尤其适用于HbA1c显著高于目标者。
  • 探索闭环系统对2型糖尿病影响的研究初步结果令人期待。
  • 评估持续葡萄糖监测在糖尿病前期(定义为糖耐量受损和/或空腹血糖受损和/或HbA1c在39 mmol/mol[5.7%]至47 mmol/mol[6.4%]之间)人群中的作用尚需进一步数据。

研究设计与样本

  • 本文为叙述性综述,描述关于技术用于2型糖尿病患者的当前知识及支持其临床应用的证据。

主要发现

  • 2型糖尿病占全球糖尿病病例的90%。
  • 仅一小部分2型糖尿病患者的血糖水平处于推荐治疗目标范围内。
  • 持续葡萄糖监测系统对接受胰岛素或非胰岛素治疗的2型糖尿病患者均有血糖获益。
  • 胰岛素泵在2型糖尿病患者中似乎安全有效,尤其适用于HbA1c显著高于目标者。
  • 闭环系统在2型糖尿病中的初步研究结果令人期待。

关键数值与推荐

  • 糖尿病前期定义为糖耐量受损和/或空腹血糖受损和/或HbA1c在39 mmol/mol[5.7%]至47 mmol/mol[6.4%]之间。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 评估持续葡萄糖监测在糖尿病前期人群中的作用尚需进一步数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The increasing incidence of type 2 diabetes, which represents 90% of diabetes cases globally, is a major public health concern. Improved glucose management reduces the risk of vascular complications and mortality; however, only a small proportion of the type 2 diabetes population have blood glucose levels within the recommended treatment targets. In recent years, diabetes technologies have revolutionised the care of people with type 1 diabetes, and it is becoming increasingly evident that people with type 2 diabetes can also benefit from these advances. In this review, we describe the current knowledge regarding the role of technologies for people living with type 2 diabetes and the evidence supporting their use in clinical practice. We conclude that continuous glucose monitoring systems deliver glycaemic benefits for individuals with type 2 diabetes, whether treated with insulin or non-insulin therapy; further data are required to evaluate the role of these systems in those with prediabetes (defined as impaired glucose tolerance and/or impaired fasting glucose and/or HbA1c levels between 39 mmol/mol [5.7%] and 47 mmol/mol [6.4%]). The use of insulin pumps seems to be safe and effective in people with type 2 diabetes, especially in those with an HbA1c significantly above target. Initial results from studies exploring the impact of closed-loop systems in type 2 diabetes are promising. We discuss directions for future research to fully understand the potential benefits of integrating evidence-based technology into care for people living with type 2 diabetes and prediabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Liarakos AL, Lim JZM, Leelarathna L, et al. The use of technology in type 2 diabetes and prediabetes: a narrative review. Diabetologia. 2024. PMID: 38951212. doi:10.1007/s00125-024-06203-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。